FTH

7.9508.52%
SS

Sona Saira Gonsalves Ramasastry

Director

Ms. Sona Saira Gonsalves Ramasastry, M.S., M. Phil., is Director of Faeth Therapeutics, Inc. (formerly known as Sensei Biotherapeutics, Inc.) from June 12, 2026. Ms. Ramasastry was Director of Invenra, Inc. since September 2024 until March 2026. She serves as Director of Engrail Therapeutics, Inc. since August 2024. She serves as Board Observer at Verge Analytics, Inc. She is Director of Kriya Therapeutics, Inc. She has been Non-Executive Independent Director of Glenmark Pharmaceuticals Limited since April 01, 2019. She served as Director at Day One Biopharmaceuticals, Inc. since March 2021 until April 23, 2026. She serves as Independent Director of Day One Biopharmaceuticals Holding Co LLC since March 2021. Ms. Ramasastry serves on the board of directors Mirum Pharmaceuticals, Inc as Independent Director since June 2022. She serves as Director of Kriya Therapeutics. She is Director at Akounos, Incorporated since June 2020. Ms. Ramasastry served as Director at Akouos, Inc. since June 2020 until December 1, 2022. She had been an Independent Director at Cassava Sciences, Inc. from February 11, 2013 to June 18, 2020. Ms. Ramasastry served as a Director at 9 Meters Biopharma, Inc. (formerly known as Innovate Biopharmaceuticals, Inc.) since June 13, 2018 until April 30, 2020. Ms. Ramasastry also associated with European Prevention of Alzheimer’s Dementia (EPAD) as Head, Business & Sustainability since 2015. Ms. Ramasastry has served as Managing Director/Managing Partner of Life Sciences Advisory, LLC, a consulting firm, since April 2009 that she founded. From August 1999 to March 2009, she was an Investment Banker with Merrill Lynch & Company, Inc., where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions (M&A), strategic and capital markets transactions. Prior to joining Merrill Lynch, she served as a Financial Analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm from July 1997 to September 1998. Ms. Ramasastry served on the Board of Directors of Sangamo Therapeutics Inc, since June 2012 until May 24, 2022. She is a Director of PTI Therapeutics and biotechnology companies. She was an Independent Director of Vir Biotechnology, Inc. since September 2019 until May 26, 2026. She serves as Advisor of Global Ventures. Ms. Ramasastry served on the Board of Directors of Repros Therapeutics, which was acquired by Allergan and serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and as the lead business advisor for the European Prevention of Alzheimer’s Dementia (EPAD) consortium. Ms. Ramasastry’s accomplishments include being named as ‘Top Life Sciences Advisor’ by Acquisition International and CorporateLiveWire. Ms. Ramasastry is a Health Innovator Fellow of the Aspen Institute and a Member of the Aspen Global Leadership Network. Ms. Ramasastry currently serves on the industry advisory Board of the Michael J Fox Foundation for Parkinson Research, as Head of business and sustainability for the European Prevention of Alzheimer Dementia (EPAD) consortium and as a special advisor for the G8 health initiatives. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University as well as an M. Phil. in Management Studies from the University of Cambridge, where she is a guest lecturer for the Bioscience Enterprise Programme and serves on the Cambridge Judge Business School Advisory Council.

Positions